

Ref No. GIL/CFD/SEC/25/325/SE

10th February 2025

BSE Limited Scrip Code: 500300 National Stock Exchange of India Limited Symbol: GRASIM

Sub: Monitoring Agency Report

Ref: Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Regulation 82(4) of the SEBI (Issue of Capital and Disclosure Requirements)

Regulation 82(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018

Dear Sirs,

Please find enclosed Monitoring Agency Report for the quarter ended 31st December 2024, issued by CARE Ratings Limited for utilisation of funds of Rights Issue of the Company. There is no variation / deviation in the utilisation of such funds.

The aforesaid information is also being made available on the website of the Company at www.grasim.com

Thanking you,

Yours sincerely, For Grasim Industries Limited

Sailesh Kumar Daga Company Secretary and Compliance Officer FCS - 4164

Encl: As above

Cc: Luxembourg Stock Exchange 35A Boulevard Joseph II L-1840 Luxembourg

Citibank N.A. Depositary Receipt Services 390 Greenwich Street,

4th Floor, New York,

NY 10013

Citibank N.A.

Custodial Services FIFC, 9th Floor, C-54 & 55,G Block Bandra Kurla Complex, Bandra (East), Mumbai - 400098



Monitoring Agency Report

No. CARE/HO/GEN/2024-25/1151

The Board of Directors Grasim Industries Limited P.O. Birlagram, Nagda – 456331 (M.P.)

February 10, 2025

Dear Sir/Ma'am,

Monitoring Agency Report for the quarter ended December 31, 2024 - in relation to the Rights issue of Grasim Industries Limited ("the Company")

We write in our capacity of Monitoring Agency for the Rights Issue for the amount aggregating to Rs. 3,999.80 crore of the Company and refer to our duties cast under 82 of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations.

In this connection, we are enclosing the Monitoring Agency Report for the quarter ended December 31, 2024 as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated January 04, 2024.

Request you to kindly take the same on records.

Thanking you, Yours faithfully,

Arti Roy Associate Director arti.roy@careedge.in

CARE Ratings Limited

Report of the Monitoring Agency

Name of the issuer: Grasim Industries Ltd For quarter ended: December 31, 2024 Name of the Monitoring Agency: CARE Ratings Limited (a) Deviation from the objects: Nil (b) Range of Deviation: Not Applicable

Declaration:

We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013.

The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit related analyses. We confirm that there is no conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer, or while undertaking credit rating or other commercial transactions with the entity.

We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title "Comments of the Board of Directors", that shall be captured by the Issuer's Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer's Management/Board.

Signature: Name and designation of the Authorized Signatory: Arti Roy Designation of Authorized person/Signing Authority: Associate Director

CARE Ratings Limited

1) Issuer Details:

Name of the issuer

: Grasim Industries Ltd

Name of the promoter : Kumar Mangalam Birla, Neerja Birla, Rajashree Birla, Vasavadatta Bajaj, Aditya Vikram Kumarmangalam Birla HUF, Ananyashree Birla, Aryaman Vikram Birla, Advaitesha Birla, Birla Consultants Ltd, Birla Industrial Finance (India) Ltd, Birla Industrial Investments (India) Ltd, Hindalco Industries Ltd, Birla Group Holdings Pvt Ltd, Rajratna Holdings Pvt Ltd, Vikram Holdings Pvt Ltd, Vaibhav Holdings Pvt Ltd, Birla Institute Of Technology And Science, Pilani Investment And Industries, Renuka Investments & Finance Ltd, IGH Holdings Pvt Ltd, Ece Industries Ltd, P.T. Indo Bharat Rayon, P T Sunrise Bumi Textiles, P T Elegant Textile Industry, Thai Rayon Public Company Ltd, Surya Kiran Investments Pte Ltd & Anatole Investments Pte Ltd.

Industry/sector to which it belongs : Producer of Cellulose, caustic soda, speciality chemicals, rayon-grade wood pulp, linen yarn, fabrics, paints, cement, financials services, renewables and B2B online marketplace for building materials.

2) Issue Details

Issue Period	: January 17, 2024 to January 29, 2024
Type of issue (public/rights)	: Rights
Type of specified securities	: Equity Shares
IPO Grading, if any	: Not Applicable
Issue size (in crore)	: Rs. 3,999.80 crore (Note 1)

Note 1:

The company had offered 2,20,73,935 Equity Shares under the rights issue, at Rs.1,812 per share (including share premium of Rs.1,810 per share) aggregating to ₹ 3,999.80 crore. The issue was Subscribed by 1.97 times; however, 3,025 shares are kept in abeyance pending regulatory/other clearances. The company has allotted 2,20,70,910 Equity Shares to the applicants aggregating to Rs.3,999.25 crore (2,20,70,910 shares X Rs.1,812). Of this, Rs.453 per share (25% of Rs.1,812), including a share premium of Rs.452.50 per share (25% of Rs.1,810), has been received as share application money, and another Rs.453 per share (25% of Rs.1,812), including a share premium of Rs.452.50 per share (25% of Rs.1,810), has been received as first call money. The balance amount shall be receivable in second and final call. Upon allotment, the company has received Rs.999.81 crore (2,20,70,910 shares X Rs.453) as share application money and Rs.994.70 crore (2,19,58,023 shares X Rs.453) as first call money.

CARE Ratings Limited

3) Details of the arrangement made to ensure the monitoring of issue proceeds:

Particulars	Reply	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of the Monitoring Agency	Comments of the Board of Directors
Whether all utilization is as per the disclosures in the Offer Document?	Yes	CA Certificate*	Nil	
Whether shareholder approval has been obtained in case of material deviations# from expenditures disclosed in the Offer Document?	Not Applicable	Not Applicable	Not Applicable	
Whether the means of finance for the disclosed objects of the issue have changed?	No	Not Applicable	Not Applicable	
Is there any major deviation observed over the earlier monitoring agency reports?	No	Not Applicable	Not Applicable	
Whether all Government/statutory approvals related to the object(s) have been obtained?	Yes	Listing approvals	Nil	
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	Not Applicable	Not Applicable	Not Applicable	
Are there any favorable/unfavorable events affecting the viability of these object(s)?	No	Not Applicable	Not Applicable	
Is there any other relevant information that may materially affect the decision making of the investors?	No	Not Applicable	Not Applicable	

*Chartered Accountant certificate from Nerkar & Co. (peer reviewed audit firm) vide CA certificate dated January 29, 2025

#Where material deviation may be defined to mean:

a) Deviation in the objects or purposes for which the funds have been raised

b) Deviation in the amount of funds actually utilized by more than 10% of the amount projected in the offer documents.

CARE Ratings Limited

4) Details of objects to be monitored:

(i) Cost of objects –

		Source of information /	Original cost	Powicod	Revised Comments		Revised Comments Comments of the Board of Directors			Directors
Sr. No	ltem Head	Source of information / certifications considered by Monitoring Agency for preparation of report	Original cost (as per the Offer Document) in Rs. Crore	(as per the OfferCostDocument) in Rs.in Rs.		Reason for cost revision	Proposed financing option	Particulars of - firm arrangements made		
1.	Repayment or prepayment, in full or in part, of certain borrowings availed by the company	Offer document	3,000.00	Not Applicable	Not Applicable					
2.	General corporate purposes	Offer document	977.65	Not Applicable	Not Applicable					
Total	Total									

(ii) Progress in the objects –

		Source of information /	Amount as	Amount	Amount utilised in Rs. Crore		utilised in Rs. Crore			Commen Board of			
Sr. No	ltem Head	certifications considered by Monitoring Agency for preparation of report	proposed in the Offer Document in Rs. Crore	proposed & received as proposed in offer document in Rs. Crore	As at beginning of the quarter in Rs. Crore	During the quarter in Rs. Crore	At the end of the quarter in Rs. Crore	Total unutilised amount in Rs. Crore	unutilised amount in	unutilised amount in	Comments of the Monitoring Agency	Reasons for idle funds	Proposed course of action
1.	Repayment or prepayment, in full or in part, of certain borrowings availed by the company	CA Certificate*	3,000.00	1,972.36	1,966.09	-	1,966.09	6.27	The funds received from rights issue proceeds were utilized towards repayments of commercial papers as per the objects of the issue.				

CARE Ratings Limited

		Source of information /	Amount as	Amount	Amount utilised in Rs. Crore				Comments of the Board of Directors		
Sr. No	ltem Head	certifications considered by Monitoring Agency for preparation of report	proposed in the Offer Document in Rs. Crore	proposed & received as proposed in offer document in Rs. Crore	As at beginning of the quarter in Rs. Crore	During the quarter in Rs. Crore	At the end of the quarter in Rs. Crore	Total unutilised amount in Rs. Crore	Comments of the Monitoring Agency	Reasons for idle funds	Proposed course of action
2.	General corporate purposes	CA Certificate*	977.65	-	-	-	-	-	Nil		
Tota			3,977.65	1,972.36	1,966.09	-	1,966.09	6.27			

*The above details are verified by Nerkar & Co. (peer reviewed audit firm) vide CA certificate dated January 29, 2025

(iii) Deployment of unutilized proceeds:

Detailed Breakup of unutilized proceeds

Particulars	Unutilised amount in Rs. Crore
Unutilized net proceeds (Rs.1,972.36 crore – Rs.1,966.09 crore)	6.27
Interest received on FD's placed	3.32^
Balance issue related expenses to be paid (Rs.22.15 crore – Rs.20.54 crore*)	1.61
Issue related expenses paid out of company's own account (other than monitoring account)	0.14
Total	11.34

*This includes Rs.0.14 crore, which the company paid from its own account (other than monitoring account). Issue expenses amounting to Rs.19.50 crore was paid till last quarter, while Rs.1.04 crore were paid in the current quarter.

^On December 10, 2024, the company redeemed its fixed deposit (FD) and created a new FD, generating an FD interest of Rs.0.03 crore. Including the Rs.3.29 crore received in FD interest up to the last quarter, the total FD interest amounted to Rs.3.32 crore.

CARE Ratings Limited

Details of Unutilized Proceeds (incl. interest accumulated on FDs)

Sr. No.	Type of instrument and name of the entity invested in	Amount invested	Maturity date	Earning	Return on Investment (%)	Market Value as at the end of quarter
1.	Axis Bank Limited – Monitoring account	Rs.1.34 crore	-	-	-	Rs.1.34 crore
2.	Axis Bank Limited – FD	Rs.4.00 crore	March 13, 2025	-	6.70%	Rs.4.01 crore
3.	Axis Bank Limited – FD	Rs.3.00 crore	September 17, 2025	-	7.40%	Rs.3.06 crore
4.	Axis Bank Limited – FD	Rs.3.00 crore	September 17, 2025	-	7.40%	Rs.3.06 crore
	Total	Rs.11.34 crore				

(iv) Delay in implementation of the object(s)

	Comp	Completion Date		Comments of the Board of Directors	
Objects	As per the offer document	Actual	Delay (no. of days/ months)	Reason of delay	Proposed course of action
Repayment or prepayment, in full or in part, of certain borrowings availed by the company	The company has until March 2026 to raise the remaining funds an can use the net proceeds by March 2027, according to the offe				
General corporate purposes	document.				

5) Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document: Not Applicable

Sr. No	Item Head^	Amount in Rs. Crore	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of Monitoring Agency	Comments of the Board of Directors
1	-	-	-	Nil	
	Total	-	-		

^ Section from the offer document related to GCP:

"The Company intends to deploy the balance Net Proceeds aggregating up to ₹977.65 crore towards general corporate purposes, provided that the amount to be utilized for general corporate purposes shall not exceed 25% of the Issue Proceeds, in compliance with the SEBI ICDR Regulations".

CARE Ratings Limited

Note: Disclosure of Interest of Independent/Non-Executive Directors of CARE:

Name of Director	Designation of Director
V. Chandrasekaran	Non-Executive - Independent Director

Mr. V. Chandrasekaran who is Non-Executive – Independent Director on the Board of Grasim Industries Ltd. is a Non-Executive – Independent Director of CARE. Independent/Non-executive Directors of CARE are not a part of CARE's Rating Committee and do not participate in the rating process.

Disclosure of Interest of Managing Director & CEO:

Not applicable

CARE Ratings Limited

Disclaimers to MA report:

a) This Report is prepared by CARE Ratings Ltd (hereinafter referred to as **"Monitoring Agency/MA"**). The MA has taken utmost care to ensure accuracy and objectivity while developing this Report based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever.

b) This Report has to be seen in its entirety; the selective review of portions of the Report may lead to inaccurate assessments. For the purpose of this Report, MA has relied upon the information provided by the management /officials/ consultants of the Issuer and third-party sources like statutory auditors (or from peer reviewed CA firms) appointed by the Issuer believed by it to be accurate and reliable.

c) Nothing contained in this Report is capable or intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The MA is also not responsible for any errors in transmission and specifically states that it, or its directors, employees do not have any financial liabilities whatsoever to the users of this Report.

d) The MA and its affiliates do not act as a fiduciary. The MA and its affiliates also do not act as an expert to the extent defined under Section 2(38) of the Companies Act, 2013. While the MA has obtained information from sources it believes to be reliable, it does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives from auditors (or from peer reviewed CA firms), lawyers, chartered engineers or other experts, and relies on in its reports.

e) The MA or its affiliates may have other commercial transactions with the entity to which the report pertains. As an example, the MA may rate the issuer or any debt instruments / facilities issued or proposed to be issued by the issuer that is subject matter of this report. The MA may receive separate compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.

CARE Ratings Limited